Cost-effectiveness of fluoxetine plus pindolol in patients with major depressive disorder: Results from a randomized, double-blind clinical trial

International Clinical Psychopharmacology

Volumn 15, Issue 2, 2000, Pages 107-113

  Sacristán, José A ^a   Gilaberte, I ^a   Boto, B ^a   Buesching, D P ^b   Obenchain, R L ^b   Demitrack, M ^b   Perez Sola V ^c   Alvarez, E ^c   Artigas, F ^d  

^a ELI LILLY AND COMPANY   (Spain)

^b ELI LILLY AND COMPANY   (United States)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d INST D INVESTIGACIONS B   (Spain)

Author keywords

Fluoxetine; Major depression; Pindodol

Indexed keywords

FLUOXETINE; PINDOLOL; SEROTONIN 1 ANTAGONIST; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; SPAIN; STATISTICAL ANALYSIS;

EID: 0034052210     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200015020-00007     Document Type: Article

References (30)

1. Artigas F, Pérez V, Alvarez E (1994) Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 52:248-249.
2. Base de datos de coste sanitarios. Versión 1.0. Barcelona: SOIKOS, 1997.
3. Bergman RM, Darnell AM, Miller HL (1997) Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 154:37-43.
4. Blier P, Bergeron R (1995) Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 15:217-222.
5. Bootman JL, Larson LN, McGhan WF, et al. (1989) Pharmacoeconomic research and clinical trials: concepts and issues. Ann Pharmacother 23:693-697.
6. Cabasés J, Gaite L, Haro JM (1996) Aproximación al coste de la esquizofrenia en España. XVI Jornadas de Economía de la Salud; Valladolid; 5-7 june.
7. Canadian Coordinating Office for Health Technology Assessment. Guidelines for Economic Evaluation of Pharmaceuticals, 2nd edn. Ottawa, Canada: CCOHT, 1997.
8. Genduso LA, Kotsanos JG (1996) Review of health economic guidelines in the form of regulations, principles, policies, and positions. Drug Inform J 30: 1003-1016.
9. Greenberg PE, Stiglin LE, Finkelstein SN (1993) The economic burden of depression in 1990. J Clin Psychiatry 54:405-418.
10. Henry JA, Rivas C (1997) Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part I: depression and its treatment. PharmacoEconomics 11:419-443.
11. Kind P, Sorenson J (1993) The cost of depression. Int Clin Psychopharmacol 7:191 -195.
12. Laska EM, Meisner M, Siegel C (1997) Statistical inference for cost-effectiveness ratios. Health Econ 6: 229-242.
13. Murray CJ, Lopez AD. The Global Burden of Disease. Geneva, Switzerland: World Health Organization, 1996.
14. Norman TR, Leonard BE (1994) Fast-acting antidepressants. Can the needs be met? CNS Drugs 2:120-131.
15. Obenchain RL. ICERconf: highly portable C-language source code for confidence intervals on incremental cost-effectiveness ratios. Indianopolis: Pharmaceutical Research and Manufacturers of America (PhRMA), 1996.
16. Obenchain RL, Melfi CA, Croghan TW, et al. (1997) Bootstrap analyses of cost-effectiveness in antidepressant pharmacotherapy. PharmacoEconomics 11:464-472.
17. Pérez V, Gilaberte I, Faries D, et al. (1997) Pindolol augments the antidepressant efficacy of fluoxetine. Lancet 349:1594-1597.
18. Polsky D, Glick HA, Eillke R, Schulman K (1997) Confidence intervals for cost-effectiveness ratios: a comparison of four methods. Health Econ 6:243-252.
19. Rudorfer MV, Manjii HK, Potter WZ (1994) Comparative tolerability profiles of the never vs. older antidepressants. Drug Safety 10:18-46.
20. Sacristán JA. Economic evaluation of drugs alongside clinical trials. In: Pharmacoeconomics: Economic Evaluation of Drugs (Sacristán JA, Badía X, Rovira J, eds) Madrid: Editores Médicos, 1995, pp. 101-114.
21. Sacristán JA, Day S, Navarro O, et al. (1995) Use of confidence intervals and sample size calculations in health economic studies. Ann Pharmacother 29:719-725.
22. Sclar DA, Robison LM, Skaer TL, Legg RF, Nemec N, Galin RS, et al. (1994) Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clin Ther 16:715-730.
23. Simon GE, VonKorff M, Heiligenstein JH, et al. (1996) Initial antidepressant choice in primary care: effectiveness and cost of fluoxetine versus tricyclic antidepressants. JAMA 275:1897-1902.
24. Song F, Freemantle N, Sheldon TA, et al. (1993) Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 306:683-687.
25. Thompson D, Buesching D, Gregor K, Oster G (1996) Patterns of antidepressant use and their relations to costs of care. Am J Managed Care 2:1239-1246.
26. Tollefson GD, Holman SL (1994) How long to onset of antidepressant action?: a meta-analysis of patients treated with fluoxetine or placebo. Int J Clin Psychopharmacol 9:245-250.
27. Tollefson GD, Holman SL, Sayler ME, et al (1994) Fluoxetine, placebo and tricyclic antidepressants in major depression with and without anxious features. J Clin Psychiatry 55:50-59.
28. Tome MB, Isaac MT, Harte R, Holland C (1997) Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol 12:81-89.
29. Vinar O, Vinarola E, Horácek J (1996) Pindolol accelerates the therapeutic action on selective serotonin reuptake inhibitors (SSRI) in depression. Homeostasis 37:93-95.
30. World Health Organization Mental Health Collaborating Centers (1989) Pharmacotherapy of depressive disorders: WHO consensus statement. J Affect Disord 17:197-198.